CD274 and triple-negative breast carcinoma: In the ALICE trial for triple-negative breast cancer, higher baseline gut microbiota alpha diversity (Faith’s PD) was significantly associated with improved efficacy of atezolizumab (anti-PD-L1) combined with chemotherapy, suggesting that microbiome features could serve as predictive biomarkers, even in PD-L1-negative patients (146).